Panel 1

Panel 1: Key Recommendations for Managing Patients With Rheumatic Diseases During The COVID-19 Epidemic

Potential risk factors for SARS-CoV-2 infection in patients with rheumatic diseases

  • On immunosuppressive agents
  • Chronic kidney disease e.g. lupus nephritis
  • With lung involvement e.g. interstitial lung disease
  • Elderly patients
  • Frequently visiting medical clinic
  • With underlying health conditions, such as smoking, obesity, hypertension and diabetes
  • Who are pregnant

 Medication for patients with rheumatic diseases #

  • Continue current treatment if disease is stable, and contact your doctor for suitable medicine if disease has flared
  • Use of hydroxychlorquine (HCQ) and sulphasalazine [SLZ] should be continued and should not increase the risk of infection
  • Use of other conventional synthetic disease modifying drugs (csDMARDs e.g. methotrexate, leflunomide) and immunosuppressants (e.g. cyclophosphamide, azathioprine, mycophenolate mofetil, tacrolimus) should be continued
  • Corticosteroid use can be continued
  • A new prescription of immunosuppressant or increase in dose of an ongoing immunosuppressant would need to be carefully discussed in epidemic areas.
  • Use of all biologic DMARDs should be continued if possible
  • If infliximab infusion is not accessible, switching to other anti-TNF injection at home is encouraged
  • Targeted synthetic DMARDs (JAK inhibitors) including Tofacitinib/ Baricitinib/ Upadacitinib can be continued


  • Postpone elective surgery e.g. joint replacement surgery
  • Screening for COVID-19 (symptoms suggestive of COVID-19, complete blood count, nasopharyngeal swab and chest x-ray or chest CT according to local recommendation) before emergency surgery

Patients with RD and fever*

  • Contact your rheumatologist about potential option to visit fever outpatient clinic with personal protection provisions if temperature continues over 38°C
  • Patients must not suddenly stop prednisolone
  • Suspend the use of immunosuppressants and biological agents after consultation with your rheumatologist, and follow appropriate local guidance for suspected COVID-19 if COVID-19 cannot be ruled out
  • Patients can continue HCQ and SLZ if they are infected with COVID-19.

# Concerning glucocorticoids, immunosuppressants, csDAMRDs, bDMARDs and JAK inhibitors, the balance of safety and efficacy in viral infection as well as pulmonary inflammation remains unclear.

slot gacor
slot thailand
anti rungkad
slot gacor malam ini
slot maxwin
mpo slot
slot thailand